Anifrolumab

Research use only, not for human use.

Anifrolumab（MEDI-546） is a potent type I interferon (IFN) receptor antagonist, a human monoclonal antibody that targets IFN.Anifrolumab inhibits the activity of type I interferon and is used for the prevention and treatment of systemic lupus erythematosus (SLE).

Anifrolumab is a type I interferon (IFN) receptor antagonist, a human monoclonal antibody. Anifrolumab blocks the activity of type I interferon. Anifrolumab can be used in systemic lupus erythematosus (SLE) research.

Anifrolumab (67.7?nM; 20 min) induces sustained reduction of surface IFNAR1 and abrogates STAT1 phosphorylation.Anifrolumab (1 and 10 μg/mL; 6 or 7 d) suppresses differentiation of B cells into plasma cells. Anifrolumab inhibits type I IFN-induced ISRE signaling, with IC50s ranging from 0.004 to 0.3?nM for the IFN-α subtypes, and 0.03?nM and 0.07?nM for IFN-β and IFN-ω, respectively.Anifrolumab (67.7?nM) dose-dependently inhibits IFN-α production from pDCs in response to CpG-A or DNA-IC stimulation, inhibiting 87-95% of IFN-α production.Western Blot Analysis Cell Line:Peripheral blood mononuclear cells (PBMCs) Concentration:67.7?nM Incubation Time:20?min Result:Abrogated IFN-α2-dependent and pDC supernatant-dependent STAT1 phosphorylation.Cell Differentiation Assay Cell Line:Plasmacytoid dendritic cell (pDC) Concentration:1 and 10 μg/mL Incubation Time:6 or 7 days Result:Inhibited pDC-mediated plasma cell differentiation in a dose-dependent manner, with a mean 76% reduction in plasma cell number relative to control antibody.

——

——

Immunology/Inflammation

Interferon Receptor

IFNAR

——

——

1326232-46-5

——

>98% (HPLC)

——

——

——

(-20℃)

With Ice Pack

≥ 2 years